Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Wins HER2 Approval, Is The ...

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

Sichuan Kelun-Biotech Biopharmaceutical received Chinese regulatory approval for its HER2 antibody drug trastuzumab botidotin following positive phase III trial results, bolstering its oncology drug portfolio and investment case amid some short-term share price pullback.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a clearer pathway to market expansion after Kelun-Biotech's HER2 approval removes a key regulatory barrier. Act fast on partnerships to leverage this nod or risk competitors filling the gap.

◆ Coverage

1 source · 15 Sep 2026

◆ Related on Wire

◆ Topics

Biotechher2china-nmpaantibody-drug-conjugateoncologyclinical-trial-success